Document Type
Article
Department
Medical College Pakistan
Abstract
Tumor lysis syndrome is a potentially lethal complication of chemotherapy, usually associated with aggressive hematologic malignancies. We describe the case of a young patient with meta-static hepatocellular cancer who developed rapid and fatal tumor lysis syndrome following ini-tiation of sorafenib therapy. Although rare with sorafenib therapy for hepatocellular carcinoma, tumor lysis syndrome is serious complication. Patients with a high burden of disease at therapy initiation should have their metabolic parameters measured prior to starting therapy and closely followed for the first 1–2 weeks while being treated
Publication (Name of Journal)
Hematology/Oncology and Stem Cell Therapy
Recommended Citation
Imam, S. Z.,
Zahid, M. F.,
Maqbool, M. A.
(2018). Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma.. Hematology/Oncology and Stem Cell Therapy, 1-3.
Available at:
https://ecommons.aku.edu/pakistan_fhs_mc_mc/98
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.